Idiopathic Intracranial Hypertension

Table of Contents

1. Overview
2. Demographics and Risk Factors
3. Secondary Causes and Diagnosis of Exclusion
4. Modified Dandy Criteria
5. Clinical Features
6. Treatment
7. Vision Monitoring and Prognosis
8. Key Research Papers
9. Connections

Overview

Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri (PTC), is a condition of elevated cerebrospinal fluid (CSF) pressure exceeding 25 cmH₂O in adults (28 cmH₂O in children) in the absence of a structural lesion, hydrocephalus, or abnormal CSF composition. The outdated term "benign intracranial hypertension" is no longer used because IIH is not benign — it can cause permanent vision loss from optic nerve damage. The condition mimics a brain tumor clinically (hence "pseudotumor cerebri") but neuroimaging reveals no mass lesion. IIH is classified as idiopathic only after secondary causes of elevated intracranial pressure have been excluded.

Demographics and Risk Factors

IIH predominantly affects women of reproductive age, with a female-to-male ratio of approximately 9:1. Obesity is present in 90% of cases, and the rising prevalence of IIH closely parallels the global obesity epidemic. The classic patient profile is an obese woman of childbearing age presenting with headache and visual disturbances.

Risk factors include:

• Obesity (BMI >30) — present in ~90% of idiopathic cases; weight gain preceding onset is common
• Female sex and reproductive age — hormonal factors implicated but not fully understood
• Recent significant weight gain (even without reaching obesity threshold)
• Certain medications: tetracyclines (doxycycline, minocycline), vitamin A/retinoids (isotretinoin for acne), oral contraceptives, corticosteroid withdrawal, recombinant growth hormone, excess levothyroxine, lithium
• Men with IIH are less common but tend to have faster vision loss and more aggressive disease — secondary causes must be investigated more thoroughly in men

Secondary Causes and Diagnosis of Exclusion

IIH is a diagnosis of exclusion. Secondary causes of elevated intracranial pressure must first be ruled out.

Medications and toxins: tetracyclines (classic board association), vitamin A and retinoids (isotretinoin prescribed for acne — well-known IIH trigger), oral contraceptives, corticosteroid withdrawal, recombinant growth hormone, excess thyroid hormone replacement, lithium, anabolic steroids.

Venous outflow obstruction: cerebral venous sinus thrombosis (must exclude with MR venography — this is critical because treatment differs fundamentally), dural arteriovenous fistula.

Systemic conditions: hypothyroidism, hypoparathyroidism, iron deficiency anemia, systemic lupus erythematosus, chronic kidney disease, hypervitaminosis A.

Diagnostic workup for exclusion:

• MRI brain with gadolinium — normal parenchyma, no mass, no hydrocephalus; may show empty sella turcica (an indirect sign of chronically elevated ICP remodeling the sella), bilateral optic nerve sheath distension, and flattening of the posterior globe
• MR venography — to exclude cerebral venous sinus thrombosis; transverse sinus stenosis is found in up to 90% of IIH, though whether this is cause or effect remains debated
• Lumbar puncture with opening pressure measurement (≥25 cmH₂O) and CSF composition analysis — protein, glucose, and cell count must all be normal
• Basic labs: CBC, CMP, TSH, vitamin A level, and a thorough medication review

Modified Dandy Criteria

The Modified Dandy Criteria are used to confirm the diagnosis of IIH:

1. Symptoms and/or signs of increased intracranial pressure: headache, papilledema, visual obscurations, diplopia from unilateral or bilateral CN VI palsy, pulsatile tinnitus
2. Lumbar puncture opening pressure ≥25 cmH₂O with normal CSF composition (protein, glucose, and cell count all normal)
3. Normal neuroimaging: no intracranial mass, no hydrocephalus, no meningeal enhancement, no structural abnormality
4. No other identifiable cause for elevated intracranial pressure

Note: IIH without papilledema (IIHWOP) is recognized as a subset where all criteria except papilledema are met. It is more common in men and in IIH related to medications.

Clinical Features

Headache (present in ~94% of patients): Daily or near-daily headache, often worse in the morning, aggravated by Valsalva maneuvers (coughing, straining), and may worsen when supine. The character is throbbing, retro-orbital, or pressure-like and can mimic migraine or tension headache. Headache in the setting of papilledema should immediately raise suspicion for IIH.

Papilledema (bilateral optic disc swelling): The hallmark finding. Elevated CSF pressure is transmitted along the optic nerve sheath, causing disc swelling visible on fundoscopy. If prolonged, papilledema leads to progressive optic nerve fiber loss and permanent visual field defects — the most feared complication of IIH.

Transient visual obscurations: Brief (seconds-long) episodes of graying, blackening, or blurring of vision provoked by changes in posture, Valsalva, or bending forward. These reflect transient optic nerve ischemia from pressure spikes.

Pulsatile tinnitus: A whooshing sound synchronous with the heartbeat, caused by turbulent venous flow through stenotic transverse sinuses under high pressure. This symptom is characteristic of IIH and is not common in most other headache disorders.

Diplopia from CN VI palsy: Unilateral or bilateral sixth nerve palsy causing horizontal diplopia. This is a false localizing sign — CN VI is injured by elevated ICP regardless of where the pressure originates, not because there is a primary CN VI lesion.

Visual field loss: Enlargement of the blind spot (enlarged physiological blind spot) is the earliest detectable change on perimetry. Progressive loss follows an inferior nasal pattern, then arcuate defect, and eventually tunnel vision. Visual field defects can become permanent if ICP is not controlled.

Cognitive symptoms: Some patients report brain fog, difficulty with concentration, and word-finding difficulties. These are underrecognized but can significantly impact quality of life.

Treatment

Weight loss (first-line for obese patients): A 10% reduction in body weight produces clinically significant improvement in intracranial pressure and papilledema. The IIH Treatment Trial (IIHTT) demonstrated that dietary weight loss intervention combined with acetazolamide was superior to either alone for improving perimetric mean deviation (visual field).

Acetazolamide: First-line pharmacological treatment. A carbonic anhydrase inhibitor that reduces CSF production at the choroid plexus. Starting dose 500 mg twice daily, titrated to 2,000–4,000 mg/day as tolerated. The IIHTT (Wall et al., 2014) showed significant improvement in visual field, papilledema grade, and ICP. Common side effects include paresthesias in hands and feet (nearly universal), dysgeusia (metallic taste of carbonated drinks), hypokalemia, kidney stone formation, and fatigue. Contraindicated in sulfa allergy.

Topiramate: An alternative or adjunct to acetazolamide. Also a carbonic anhydrase inhibitor with the added benefit of promoting weight loss. Useful when acetazolamide is not tolerated.

Furosemide: Second-line diuretic. Used when acetazolamide alone is insufficient or poorly tolerated.

Surgical options for vision-threatening IIH:

• Optic nerve sheath fenestration (ONSF): Surgical incisions made in the dura surrounding the optic nerve behind the globe, creating a pressure-release valve that protects the optic nerve from ICP transmission. Primarily prevents vision loss rather than treating headache. Indicated for rapid vision loss when medical treatment is insufficient or fails.
• CSF shunting (lumboperitoneal or ventriculoperitoneal shunt): Diverts CSF to the peritoneal cavity to reduce ICP. Effective for both headache and vision protection but associated with high revision rates due to shunt malfunction and overshunting causing low-pressure headache. Used for severe refractory headache unresponsive to medication and vision loss.
• Transverse venous sinus stenting: An emerging endovascular procedure. Stenting stenotic transverse sinuses reduces the downstream venous pressure that contributes to elevated ICP. Promising results in select patients with demonstrable venous sinus stenosis and a measurable pressure gradient.

Repeat lumbar puncture: Provides temporary ICP reduction. Primarily used diagnostically or as a temporary bridge while awaiting surgical intervention. Not a long-term solution.

Vision Monitoring and Prognosis

Serial visual field testing with Humphrey automated perimetry (24-2 program) every 1–3 months during active disease is essential. Optical coherence tomography (OCT) of the retinal nerve fiber layer (RNFL) provides objective measurement of optic nerve damage. Fundoscopy to grade papilledema should be performed at each visit.

With timely weight loss and medical treatment, most patients achieve ICP control and vision stabilization. Vision loss occurs in 10–25% of patients; severe vision loss in approximately 5%. Recurrence is common with weight regain. Chronic intractable headache persists in some patients even after ICP normalization. Pregnancy can trigger IIH exacerbation, but most pregnancies in IIH patients are managed safely with acetazolamide cessation in the first trimester and close monitoring.

Key Research Papers

1. Wall M, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol. 2014;71(6):693-701. PMID: 24756050.
2. Wall M, et al. The idiopathic intracranial hypertension treatment trial: visual acuity and visual field outcomes. Ophthalmology. 2015;122(1):7-14. PMID: 25277242.
3. Mollan SP, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088-1100. PMID: 30061319.
4. Friedman DI, et al. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013;81(13):1159-1165. PMID: 23966248.
5. Markey KA, et al. Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurol. 2016;15(1):78-91. PMID: 26700914.
6. Celebisoy N, et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007;116(5):322-327. PMID: 17922725.
7. Berdahl JP, et al. Transverse venous sinus stenting for idiopathic intracranial hypertension: 12-month results from a prospective treatment algorithm. J Neurointerv Surg. 2020;12(11):1065-1071. PMID: 32241877.
8. Thurtell MJ, Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Curr Treat Options Neurol. 2013;15(1):1-12. PMID: 23143617.
9. Rowe FJ, Sarkies NJ. The relationship between obesity and idiopathic intracranial hypertension. Int J Obes Relat Metab Disord. 1999;23(1):54-59. PMID: 10094577.
10. Kesler A, et al. Idiopathic intracranial hypertension: the prevalence and incidence. J Neuroophthalmol. 2014;34(3):227-231. PMID: 24816148.
11. Thambisetty M, et al. Fulminant idiopathic intracranial hypertension. Neurology. 2007;68(3):229-232. PMID: 17224587.
12. McGeeney BE, Friedman DI. Pseudotumor cerebri pathophysiology. Headache. 2014;54(3):445-458. PMID: 24601999.

Connections

• Migraine
• Normal Pressure Hydrocephalus
• Chiari Malformation
• Cerebral Venous Thrombosis
• Neurology Diseases
• Vitamin A (retinoid toxicity trigger)
• Epilepsy
• Multiple Sclerosis

↑ Back to Table of Contents